편두통 : 세계 주요 7개국 의약품 시장 예측 및 시장 분석

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Migraine market through 2033.

GlobalData estimates that the value of the migraine market in the 7MM in 2023 was $9.2 billion. This market is defined as sales of acute and preventatitve treatments including widely used triptans and ergot alkaloids used in abortive treatment amongst others as well as oral preventive therapies such as antidepressants, anticonvulsants, and beta blockers and the newer CGRP-targeting mAbs or gepants across the 7MM. Among these sales, $7.5 billion (81.5%) were generated in the US, with the 5EU representing the next largest region by sales, with an estimated $1.5 billion (15.9%). Japan generated the lowest sales, with an estimated $241 million (2.6%).

By the end of the forecast period in 2033, GlobalData projects female infertility sales to rise to $16.4 billion in the 7MM, at a modest compound annual growth rate (CAGR) of 6.0%.

Scope

• Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM migraine therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM migraine therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Migraine: Executive Summary

• 1.1 Migraine therapeutics market will grow to $16.4 billion.
• 1.2 Key players will maintain their competitive position.
• 1.3 Environmental unmet needs remain key challenge in migraine market.
• 1.4 Lack of novelty in late-stage acute pipeline
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Classification
• 3.3 Staging

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities.
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology.
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods.
  • 4.4.3 12-month total prevalent cases of migraine
  • 4.4.4 12-month total prevalent cases of migraine by frequency
  • 4.4.5 12-month total prevalent cases of migraine by type
  • 4.4.6 12-month diagnosed prevalent cases of migraine
  • 4.4.7 12-month diagnosed prevalent cases of migraine by frequency
  • 4.4.8 12-month diagnosed prevalent cases of migraine by type
• 4.5 Epidemiological forecast for migraine (2023-33)
  • 4.5.1 12-month total prevalent cases of migraine
  • 4.5.2 Age-specific 12-month total prevalent cases of migraine
  • 4.5.3 Sex-specific 12-month total prevalent cases of migraine
  • 4.5.4 12-month total prevalent cases of migraine by frequency
  • 4.5.5 12-month total prevalent cases of migraine by type
  • 4.5.6 12-month diagnosed prevalent cases of migraine
  • 4.5.7 Age-specific 12-month diagnosed prevalent cases of migraine.
  • 4.5.8 Sex-specific 12-month diagnosed prevalent cases of migraine.
  • 4.5.9 12-month diagnosed prevalent cases of migraine by frequency
  • 4.5.10 12-month diagnosed prevalent cases of migraine by type
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Access to effective prophylactic treatments
• 7.3 Treatments for refractory patients'
• 7.4 Physician education for diagnosis
• 7.5 Raise awareness of the disease in the general population

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Novel MOAs
  • 8.1.2 Combination therapies
  • 8.1.3 Reformulations
• 8.2 Clinical trials design
  • 8.2.1 Study design
  • 8.2.2 Endpoints
  • 8.2.3 Patient recruitment

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment
  • 10.2.1 Acute therapies
  • 10.2.2 Preventive therapies

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Managing Epidemiologist
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• 13.7 Contact Us